Method and compositions for preventing tumor development and metastasis
AssigneeThe Administrators of the Tulane Educational Fund
InventorsEckhard ALT, Reza IZADPANAH
Life of this patent
Estimating the term…
Abstract
A method for preventing and treating micrometastasis in a patient with cancer, especially breast cancer or glioblastoma tumors, by silencing TRAF3IP2 before during or in connection with treatment as described herein.
Claims35
A method of preventing surgery-, diagnostic- or intervention-related micrometastasis on a subject having cancer, wherein the cancer cells have increased TRAF3IP2 expression in comparison with a non-cancer cell, said method comprising the steps of:
- a) administering a pharmaceutical composition into the subject, and
- b) performing (i) surgery to treat the cancer, (ii) diagnostic for the cancer, or (iii) intervention to treat the cancer;
- c) wherein the pharmaceutical composition comprises at least one targeting sequence for TRAF3IP2 in a pharmaceutically acceptable carrier in an amount effective for the prevention of micrometastasis.
A method of treating a patient with cancer, the cancer having increase in TRAF3IP2 expression as compared to a normal cell, said method comprising the steps of:
- a) administering a pharmaceutical composition into a subject before, during or in connection with at least one of the following procedure:
- surgery, diagnostic or therapeutic intervention, chemotherapy, radiation therapy, immunotherapy or targeted intervention;
- b) wherein the pharmaceutical composition comprises at least one targeting sequence for TRAF3IP2 in a pharmaceutically acceptable carrier in an amount effective for prevention of micrometastasis, wherein the targeting sequence suppresses expression of TRAF3IP2.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of determining malignancy of a tumor in a patient, comprising the steps of:
- a) obtaining a biological sample from a patient;
- and
- b) detecting presence of a unspliced TRAF3IP2 in the biological sample;
- wherein the presence of the unspliced TRAF3IP2 in the biological sample indicates malignancy of the tumor.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.